0
Signin
countryflagUS

18889881171

AAPL 173.18 2.2918% MSFT 397.84 0.7343% GOOG 168.46 1.7455% GOOGL 166.62 1.6844% AMZN 184.72 3.1955% NVDA 858.11 3.3357% META 441.84 0.6034% TSLA 180.1 0.0611% TSM 136.23 0.956% LLY 755.91 -2.683% V 267.61 0.1085% AVGO 1238.3 -0.3669% JPM 191.66 -0.1042% UNH 492.97 1.8302% NVO 124.02 -4.0167% WMT 59.71 1.4613% LVMUY 164.94 0.5609% XOM 116.24 0.181% LVMHF 825.49 0.3843% MA 441.1 -0.2194%

Amylyx Pharmaceuticals Inc

Healthcare US AMLX

2.0USD
0.07(3.63%)

Last update at 2024-05-02T20:11:00Z

Day Range

1.932.05
LowHigh

52 Week Range

11.8241.93
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -197.60100M -87.93100M -42.28000M -13.71600M
Minority interest - - - -
Net income -198.37500M -87.87900M -44.83700M -14.81600M
Selling general administrative 127.13M 38.93M 15.06M 3.08M
Selling and marketing expenses - - - -
Gross profit 19.24M 0.28M 0.65M -
Reconciled depreciation 0.49M 0.05M 0.00100M 0.00000M
Ebit -201.82800M -82.74000M -39.00500M -13.55400M
Ebitda -201.34100M -82.68800M -38.72100M -13.37900M
Depreciation and amortization 0.49M 0.05M 0.28M 0.17M
Non operating income net other 3.74M - - -
Operating income -201.34100M -82.68800M -39.00500M -13.55400M
Other operating expenses 223.57M 82.69M 39.01M 13.55M
Interest expense 4.29M 0.04M 2.29M 1.28M
Tax provision 0.77M - - -
Interest income 4.29M 0.04M 0.01M 0.18M
Net interest income 4.29M 0.04M -2.27400M -1.10000M
Extraordinary items - - - -
Non recurring - - - -
Other items - - - -
Income tax expense 0.77M -0.05200M 2.56M 1.10M
Total revenue 22.23M 0.28M 0.65M 0.00000M
Total operating expenses 220.58M 82.69M 39.01M 13.55M
Cost of revenue 2.99M - - -
Total other income expense net 3.74M -5.24300M -3.27500M -0.16200M
Discontinued operations - - - -
Net income from continuing ops -198.37500M -87.93100M -42.28000M -13.71600M
Net income applicable to common shares -198.37500M -87.93100M -42.28000M -13.71600M
Preferred stock and other adjustments - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 391.45M 105.61M 14.10M 3.22M
Intangible assets - - - -
Earning assets - - - -
Other current assets 10.11M 8.83M 0.76M 0.14M
Total liab 50.85M 256.78M 80.83M 28.58M
Total stockholder equity 340.61M -151.16800M -66.72500M -25.35700M
Deferred long term liab - - - -
Other current liab -2.04000M 13.02M 3.71M 2.33M
Common stock 0.00700M 0.00100M 0.00100M 0.00100M
Capital stock 0.00700M 0.00100M 0.00100M 0.00100M
Retained earnings -354.22000M -155.84500M -67.91400M -25.63400M
Other liab - 0.04M 0.02M 1.44M
Good will - - - -
Other assets 1.19M 0.19M 0.31M 0.02M
Cash 346.94M 96.12M 12.88M 3.06M
Cash and equivalents - - - -
Total current liabilities 46.61M 17.40M 7.33M 4.53M
Current deferred revenue - - - -
Net debt -340.66800M -96.11800M -11.45200M 11.87M
Short term debt 2.04M - - -
Short long term debt - - - -
Short long term debt total 6.28M - 1.43M 14.93M
Other stockholder equity 303.45M -3.00800M 1.19M 0.28M
Property plant equipment 2.61M 0.47M 0.15M -
Total current assets 382.13M 101.51M 13.64M 3.20M
Long term investments - - - -
Net tangible assets 340.61M -151.16800M -66.72500M -25.35700M
Short term investments 284.42M 45.93M - -
Net receivables 15.31M - - -
Long term debt - - 1.43M 14.93M
Inventory 9.77M - - -
Accounts payable 46.61M 17.40M 3.61M 2.19M
Total permanent equity - - - -
Noncontrolling interest in consolidated entity - - - -
Temporary equity redeemable noncontrolling interests - - - -
Accumulated other comprehensive income -0.08600M 0.00900M - -
Additional paid in capital - - - -
Common stock total equity 0.00700M - - -
Preferred stock total equity - - - -
Retained earnings total equity -354.22000M - - -
Treasury stock - - - -
Accumulated amortization - - - -
Non currrent assets other 1.19M 3.63M 0.31M 0.02M
Deferred long term asset charges - - - -
Non current assets total 9.32M 4.10M 0.47M 0.02M
Capital lease obligations 6.28M - - -
Long term debt total - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -236.46200M -46.40600M -46.05300M -46.05300M
Change to liabilities 1.85M 0.67M 1.42M 1.28M
Total cashflows from investing activities -238.98800M -46.40600M -0.15100M -0.15100M
Net borrowings - 25.90M 16.82M 0.64M
Total cash from financing activities 431.79M 158.51M 46.82M 0.67M
Change to operating activities 21.58M 3.92M 1.18M 2.22M
Net income -198.37500M -87.93100M -42.28000M -13.71600M
Change in cash 12.87M 37.31M 9.97M -10.01900M
Begin period cash flow 50.38M 13.07M 3.09M 13.11M
End period cash flow 63.24M 50.38M 13.07M 3.09M
Total cash from operating activities -179.87100M -74.79900M -36.69700M -10.68700M
Issuance of capital stock 432.45M 135.00M 29.96M 0.00000M
Depreciation 0.49M 0.05M 0.00100M 0.00100M
Other cashflows from investing activities - - - -
Dividends paid - - - -
Change to inventory -9.76900M -9.76900M -9.76900M -9.76900M
Change to account receivables -15.30600M -15.30600M -15.30600M -15.30600M
Sale purchase of stock 434.64M - - -
Other cashflows from financing activities -0.65800M 23.77M -0.15100M 0.67M
Change to netincome 21.71M 8.48M 2.98M -0.47500M
Capital expenditures 2.53M 0.35M 0.15M 0.15M
Change receivables -14.81900M - - -
Cash flows other operating 21.09M - - -
Exchange rate changes - - - -
Cash and cash equivalents changes 12.93M - - -
Change in working capital -1.64100M 4.59M 2.60M 3.50M
Stock based compensation 21.71M 3.14M 0.24M 0.11M
Other non cash items -2.05600M 5.23M 1.74M -0.58300M
Free cash flow -182.39700M -75.15200M -36.84800M -10.68700M

Fundamentals

  • Previous Close 1.93
  • Market Cap981.71M
  • Volume1909271
  • P/E Ratio1454.00
  • Dividend Yield-%
  • EBITDA-6.75600M
  • Revenue TTM294.22M
  • Revenue Per Share TTM4.41
  • Gross Profit TTM -74.21300M
  • Diluted EPS TTM0.01

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
AMLX
Amylyx Pharmaceuticals Inc		 0.07 3.63% 2.00 1454.00 15.90 3.17 2.26 2.02 -87.8658
NVO
Novo Nordisk A/S		 -5.19 4.02% 124.02 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -2.236 1.77% 124.22 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -1.98 0.49% 400.16 30.40 24.75 10.68 6.25 9.52 20.36
CSLLY
CSL Ltd		 1.91 2.14% 91.05 42.45 26.95 7.05 5.80 7.85 26.51

Reports Covered

Stock Research & News

View All

Profile

Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Amylyx Pharmaceuticals Inc

43 Thorndike Street, Cambridge, MA, United States, 02141

Key Executives

Name Title Year Born
Mr. Joshua B. Cohen Co-Founder, Co-CEO & Director 1992
Mr. Justin B. Klee Co-Founder, Co-CEO & Director 1991
Mr. James M. Frates M.B.A. Chief Financial Officer 1967
Ms. Margaret M. Olinger M.B.A Global Head of Commercial & Chief Commercial Officer 1965
Mr. Tom Holmes Chief Technical Operations Officer NA
Ms. Gina M. Mazzariello Chief Legal Officer & Gen. Counsel 1971
Ms. Shauna Horvath Head of Global Marketing NA
Ms. Debra L. Canner Global Head of HR & CHRO 1959
Dr. Patrick D. Yeramian M.D., MBA, Ph.D. Global Head of Clinical R&D and Chief Medical Officer 1959
Mr. Chris Aiello Head of Canada & GM NA

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).